MedTrace Logo

CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer

NCT03916367 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2019-05-21

No results posted yet for this study

Summary

This study observes the efficacy and side effects of CT-guided radioactive iodine-125 seed brachytherapy in inoperable early stage non-small cell lung cancer retrospectively, and analyzes the influence of clinical and dosimetric factors on the outcomes.

Conditions

  • Early Stage Non-small Cell Lung Cancer

Interventions

RADIATION

CT-guided Radioactive I-125 Seeds Implantation

The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Junjie Wang, M.D. Ph.D. · Department of Radiation Oncology, Peking University Third Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-15
Primary Completion
2018-12-15
Completion
2019-02-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03916367 on ClinicalTrials.gov